Americans pay significantly more for prescription medications, with branded drugs in the U.S. costing about three times more than those in other countries.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

President Donald Trump took aim at that pricing disparity with an executive order on May 12 that aims to lower drug prices for U.S. consumers and taxpayers, sharing on social media that they'd be cut by "59%,

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

The cost of prescription drugs have risen rapidly despite policymakers pledging to fix the issue. They climbed nearly 40% since 2014, according to data from GoodRx.

President Donald Trump signed an executive order aimed at cutting prescription drug prices. The plan won’t be limited to Medicare prescriptions but will also target medications covered by Medicaid and private insurance.

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year.

President Donald Trump's effort to reduce prices of prescription drugs amounts to price control since it’s not limited to just government programs, according to one expert.

Trump claimed his proposed plan to tie drug prices to those paid in foreign nations would lower by up to 90% the payments by the U.S., although experts said it’s unclear if the plan is legal